Aytu BioPharma Inc (AYTU)

Healthcare | Drug Manufacturers Specialty Generic
Income Statement (Quarterly) 2025-03-31 2024-12-31 2024-09-30 2024-06-30
Revenue 18,452,000 16,221,000 16,574,000 17,976,000
Cost of Revenue 5,646,000 5,435,000 4,589,000 6,070,000
Gross Profit 12,806,000 10,786,000 11,985,000 11,906,000
Operating Expenses
R&D Expenses 0 0 0 0
SG&A Expenses 9,303,000 9,721,000 10,784,000 11,088,000
Operating Expenses 9,465,000 12,481,000 11,210,000 15,556,000
Operating Income 2,421,000 -1,695,000 -930,000 -3,650,000
Interest Expense -900,000 1,079,000 994,000 0
Income Before Tax 3,818,000 382,000 1,498,000 -3,922,000
Income Tax Expense 122,000 -283,000 405,000 695,000
Net Income 3,994,000 788,000 1,474,000 -4,617,000
Per Share
EPS 0.01 0.13 0.20 -0.83
EPS Diluted 0.00 0.00 0.00 0.00
Income Statement (Annual) 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Revenue 66,382,000 81,002,000 107,399,000 96,669,000 65,632,000
Cost of Revenue 20,551,000 26,416,000 40,767,000 44,386,000 36,432,000
Gross Profit 45,831,000 54,586,000 66,632,000 52,283,000 29,200,000
Operating Expenses
R&D Expenses 0 0 0 0 0
SG&A Expenses 38,285,000 49,472,000 70,078,000 69,880,000 55,808,000
Operating Expenses 39,611,000 60,570,000 83,697,000 88,386,000 67,440,000
Operating Income -7,827,000 -5,254,000 -17,065,000 37,215,000 -58,870,000
Interest Expense 3,703,000 4,792,000 4,963,000 147,498,000 0
Income Before Tax -13,745,000 -14,076,000 -17,051,000 -110,283,000 -58,030,000
Income Tax Expense 437,000 1,768,000 -57,000 -110,000 259,000
Net Income -13,562,000 -15,844,000 -17,051,000 -110,173,000 -58,289,000
Per Share
EPS -2.16 -2.86 -5.11 -1,499.10 -0.17
EPS Diluted 0.00 0.00 0.00 0.00 0.00
Balance Sheet (Quarterly) 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Assets
Cash and Cash Equivalents 30,952,000 20,006,000 22,985,000 19,360,000
Short Term Investments 0 0 0 0
Net Receivables 31,155,000 23,617,000 28,937,000 21,712,000
Inventory 11,434,000 12,633,000 11,995,000 10,849,000
Total Current Assets 79,179,000 61,891,000 72,832,000 59,929,000
Property Plant Equipment 1,593,000 1,522,000 3,869,000 6,296,000
Goodwill and Intangibles 42,201,000 52,453,000 58,970,000 70,632,000
Total Assets 124,177,000 118,095,000 136,463,000 137,623,000
Liabilities
Account Payables 10,601,000 10,440,000 13,478,000 10,987,000
Short Term Debt 1,857,000 4,964,000 85,000 3,909,000
Total Current Liabilities 63,064,000 62,228,000 69,015,000 64,442,000
Long Term Debt 11,880,000 11,454,000 14,713,000 14,279,000
Total Liabilities 105,211,000 90,379,000 97,106,000 91,531,000
Shareholders Equity
Retained Earnings -333,535,000 -319,973,000 -304,129,000 -288,472,000
Total Shareholders Equity 18,966,000 27,716,000 39,357,000 46,092,000
Balance Sheet (Annual) 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Assets
Cash and Cash Equivalents 30,952,000 20,006,000 22,985,000 19,360,000 49,649,000
Short Term Investments 0 0 0 0 0
Net Receivables 31,155,000 23,617,000 28,937,000 21,712,000 28,176,000
Inventory 11,434,000 12,633,000 11,995,000 10,849,000 16,339,000
Total Current Assets 79,179,000 61,891,000 72,832,000 59,929,000 105,234,000
Property Plant Equipment 1,593,000 1,522,000 3,869,000 6,296,000 8,703,000
Goodwill and Intangibles 42,201,000 52,453,000 58,970,000 70,632,000 151,266,000
Total Assets 124,177,000 118,095,000 136,463,000 137,623,000 265,668,000
Liabilities
Account Payables 10,601,000 10,440,000 13,478,000 10,987,000 19,255,000
Short Term Debt 1,857,000 4,964,000 85,000 3,909,000 25,542,000
Total Current Liabilities 63,064,000 62,228,000 69,015,000 64,442,000 109,438,000
Long Term Debt 11,880,000 11,454,000 14,713,000 14,279,000 2,804,000
Total Liabilities 105,211,000 90,379,000 97,106,000 91,531,000 128,100,000
Shareholders Equity
Retained Earnings -333,535,000 -319,973,000 -304,129,000 -288,472,000 -178,299,000
Total Shareholders Equity 18,966,000 27,716,000 39,357,000 46,092,000 137,568,000
Cash Flow Statement (Quarterly) 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Operating Activities
Net Income -13,562,000 -15,844,000 -17,051,000 -110,173,000
Depreciation & Amortization 5,377,000 8,272,000 8,815,000 10,251,000
Stock Based Compensation 576,000 2,913,000 6,046,000 5,248,000
Change in Working Capital -5,733,000 -4,660,000 -5,798,000 -10,863,000
Operating Cash Flow -1,937,000 -1,388,000 -5,129,000 -28,823,000
Investing Activities
Capital Expenditure -228,000 0 0 0
Investments -228,000 0 0 0
Investing Cash Flow -2,560,000 -329,000 -117,000 -3,248,000
Financing Activities
Debt Repayment 603,000 -1,890,000 -2,346,000 -172,458,000
Common Stock Issued/Repurchased 14,840,000 3,467,000 15,575,000 11,694,000
Dividends Paid 0 0 0 0
Financing Cash Flow 15,443,000 -1,262,000 8,871,000 1,530,000
Summary
Free Cash Flow -2,165,000 -1,388,000 -5,129,000 -28,823,000
Net Change in Cash 10,946,000 -2,979,000 3,625,000 -30,541,000
Cash Flow Statement (Annual) 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Operating Activities
Net Income -13,562,000 -15,844,000 -17,051,000 -110,173,000 -58,289,000
Depreciation & Amortization 5,377,000 8,272,000 8,815,000 10,251,000 9,201,000
Stock Based Compensation 576,000 2,913,000 6,046,000 5,248,000 3,574,000
Change in Working Capital -5,733,000 -4,660,000 -5,798,000 -10,863,000 1,681,000
Operating Cash Flow -1,937,000 -1,388,000 -5,129,000 -28,823,000 -25,964,000
Investing Activities
Capital Expenditure -228,000 0 0 0 0
Investments -228,000 0 0 0 0
Investing Cash Flow -2,560,000 -329,000 -117,000 -3,248,000 -2,782,000
Financing Activities
Debt Repayment 603,000 -1,890,000 -2,346,000 -172,458,000 -54,947,000
Common Stock Issued/Repurchased 14,840,000 3,467,000 15,575,000 11,694,000 45,051,000
Dividends Paid 0 0 0 0 0
Financing Cash Flow 15,443,000 -1,262,000 8,871,000 1,530,000 30,314,000
Summary
Free Cash Flow -2,165,000 -1,388,000 -5,129,000 -28,823,000 -25,964,000
Net Change in Cash 10,946,000 -2,979,000 3,625,000 -30,541,000 1,568,000